Der entscheidende Satz: May 14, 2012, Matthew Schissler has resigned his position as Chairman, CEO, and Secretary, and as a Director of Cord Blood America. Mr. Schissler is also no longer an officer or director with any of the Company's wholly owned subsidiaries.
: Cord Blood America Announces Change in Management
LAS VEGAS, May 15, 2012 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC BB: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that, effective May 14, 2012, Matthew Schissler has resigned his position as Chairman, CEO, and Secretary, and as a Director of Cord Blood America. Mr. Schissler is also no longer an officer or director with any of the Company's wholly owned subsidiaries.
Joseph R. Vicente, who had been Chief Operating Officer and Vice President of the Company prior to May 15th, was appointed Chairman and President by the Board of Directors on May 15th. Mr. Vicente joined the Company as a Director of Cord Blood America in April 2004. He previously served as an independent consultant to companies, providing strategic consulting services on acquisitions, operational practices and efficiencies and sales management. Mr. Vicente, who earned an MBA from the University of Tampa, has also held various executive positions with profit and loss responsibility for System One/TMP Worldwide, Inc.
The Board of Directors on May 15th also named Stephen Morgan as the Company's Vice President and Secretary. He has served as General Counsel for the Company since August 2010 and will also remain in that role. A graduate of Loyola Law School in Los Angeles, prior to working for the Company Mr. Morgan represented clients in a broad range of transactional and litigation matters working for law firms in the Los Angeles area.
: Cbai Announces First Quarter Financial Results
LAS VEGAS, May 21, 2012 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that revenues for the first quarter of 2012 increased by 6.7% to $1.55 million compared to $1.45 in the same period last year. The Company announced a gross profit of $1.12 million in the first quarter of 2012, an increase of 13.6% compared to the same period of 2011. The Company's loss from operations narrowed to $0.26 million from a prior year period of $1.43 million, a decrease of 81%.
"Today's results serve as a baseline by which to benchmark our performance in the quarters ahead," said newly appointed President Joseph Vicente. "Management understands that it will be held accountable to improve upon these results. We need to build shareholder value," Mr. Vicente said.
Mr. Vicente broke down further key financial metrics for the Quarter:
Revenues increased moderately by 6.7%. He said that in 2011, the larger quarter over quarter increases reported were primarily driven by the full impact of two acquisitions being consolidated into the financials. Going forward, the revenues will more clearly indicate the Company's organic growth rate. Gross profit continues to be a strength of the Company with its gross margin up over 72%. We are pleased with the overall efficiency with our laboratory operations. We know that capacity remains with our laboratory and we will focus on quality enhancements to further leverage that capacity. The Company's loss from operations was reduced by approximately $1.2 million from the first quarter of 2011 to the first quarter of 2012. It is important to note this number does include depreciation and amortization, as well as some interest income. We are concentrating on a positive EBITDA performance for our operations, as we believe it is a critical component to creating company value. We will be disciplined with each dollar spent. We will not be biased to post growth just for growth. As we dissect the business, we always will assess the cost to obtain an additional dollar of revenue.
Finally, we continue to assess our approximately $2.3 million in existing principal debt versus an outstanding share count that has reached the ceiling of the authorized. We are exploring different alternatives. We recognize that in light of these debt obligations the cash value from the reoccurring sample base alone should provide more than ample coverage, thus providing us the opportunity to execute a viable business strategy.
"The next 90-120 days will be very tactical as we evaluate each and every segment of the business, with the goal of ensuring a financially sound footprint, along with a stable platform to grow. We remain excited about the possibilities, but we also understand this enthusiasm will only carry momentum with positive results," Mr. Vicente said.
...was das "Phänomen" Börse ausmacht, dass es eben nicht erklärbar ist und jetzt sage mir nicht, dass du tatsächlich daran glaubst, dass ein Kurs steigen muss, "nur" weil die Zahlen gut sind...Angebot und Nachfrage ist die einzige Antwort...oder etwa doch 42... http://www.die-antwort-auf-alle-fragen.de/
Translated by google; ....freut sich bekanntzugeben, hat eine Vereinbarung mit den Menschen, bei denen CBAI erwarb ihre Mehrheitsbeteiligung an BioCordcell (Biozellen) Argentina SA in Bezug auf die 2011 Earn-out, die zuvor in Streit wie in der Gesellschaft jüngsten 10Q und 10K eingereichten Unterlagen offengelegt abgeschlossen.
Die Bedingungen des Abkommens schränken die Barauszahlung an die Verkäufer im Jahr 2012 auf $ 60.000. Darüber hinaus sieht das Abkommen die zukünftigen Cash-Beträge, um nicht zu $ 440.000 übersteigen, um durch CBAI den prozentualen Anteil der Dividenden ausschließlich auf Biozellen "operative Performance in 2012 und 2013 basieren bezahlt werden. Diese Struktur sollte auch umgekehrt einen Teil der bisherigen Rückstellung im Zusammenhang mit der 2011 Earn-out-Betrag in der Bilanz für das Jahr endend 2011 gebucht, und negiert jede weitere Bilanz Haftung, die aufgezeichnet worden konnte nach oben von $ 455.000, wenn keine solche Einigung erzielt wurde, .
"Ich bin sehr erfreut, dass die Verkäufer von Biozellen, durch Diego Rissola, Präsident der Biozellen, und Cord Blood America Management nicht nur in der Lage, eine Vereinbarung über die letzten Jahr des Earn-out zu erreichen, aber auch den umfassenden Dialog zu stärken mehrere Komponenten der Beziehung, wird eine Hebelwirkung auf die beiden Einheiten in den kommenden Jahren ", sagte Chairman und Präsident Joseph Vicente....
Diese Arschgeigen sollten vernichtet werden.Das ist doch eine Betrügerbude hoch zehn.Scheiß Amipack.Bei mir sieht es genauso aus.Wenn mir dieser Vincent mal über den weg laufen sollte, kann er sich warm anziehen, diese Mistsau.